ADMA Biologics Q4 2023 Earnings Report $18.01 -1.44 (-7.40%) As of 04:00 PM Eastern Earnings HistoryForecast ADMA Biologics EPS ResultsActual EPS$0.04Consensus EPS $0.02Beat/MissBeat by +$0.02One Year Ago EPSN/AADMA Biologics Revenue ResultsActual Revenue$73.90 millionExpected Revenue$73.50 millionBeat/MissBeat by +$400.00 thousandYoY Revenue GrowthN/AADMA Biologics Announcement DetailsQuarterQ4 2023Date2/28/2024TimeN/AConference Call ResourcesPress ReleaseADMA Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Remove Ads ADMA Biologics Earnings HeadlinesTrump Tariffs: President Says U.S. Industries To Be 'Reborn'; S&P 500 Futures Rise (Live Coverage)April 2 at 4:54 PM | msn.comAdma Biologics (ADMA) Stock Moves -0.15%: What You Should KnowMarch 29, 2025 | msn.comTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 4, 2025 | Porter & Company (Ad)How IBD Stock Of The Day ADMA Biologics Shrugged Off Accounting Debacle For A Bullish ComebackMarch 27, 2025 | msn.comADMA Biologics: Premium Valuation Justified By Strong Fundamentals And Future PotentialMarch 21, 2025 | seekingalpha.comStock Market Jumps After Powell Commentary; Breakouts Still Sparse, But LandBridge Passes MusterMarch 20, 2025 | msn.comSee More ADMA Biologics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ADMA Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ADMA Biologics and other key companies, straight to your email. Email Address About ADMA BiologicsADMA Biologics (NASDAQ:ADMA), a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.View ADMA Biologics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Lamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go Higher Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
